Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

$65M round positions SQZ Biotech for potential IPO, 2021 catalysts

Stephen Hansen, Associate Editor
May 18, 2020 11:45 PM UTC

SQZ Biotech is adding at least one experienced crossover investor to what could be its last private financing ahead of catalysts expected late this year and next.

SQZ Biotechnologies Co. raised $65 million in a series D round led by new investor Temasek, bringing its total of private capital raised to $167 million. Existing investors GV, Illumina Ventures, Invus, JDRF T1D Fund, NanoDimension and Polaris Partners also participated, along with a new investor in an undisclosed U.S. fund...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

SQZ Biotechnologies Co.